Rivafoli 2.5 Tablet contains Rivaroxaban 2.5 mg, a direct oral anticoagulant (DOAC) that helps prevent blood clot formation and reduce the risk of stroke in patients with atrial fibrillation, deep vein thrombosis (DVT), or pulmonary embolism (PE).
Belonging to the cardiology and anti-coagulant segment, Rivaroxaban is widely prescribed for both prophylaxis and treatment of thromboembolic events. Its oral administration provides convenience and adherence compared to traditional injectable anticoagulants.
The medicine works by selectively inhibiting Factor Xa, which prevents the conversion of prothrombin to thrombin, thereby reducing clot formation and maintaining normal blood flow. This mechanism is vital for cardiovascular patients at risk of recurrent events.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Rivafoli 2.5 Tablet offers a profitable B2B opportunity, catering to hospitals, cardiology clinics, and specialty pharmacies across India. Its therapeutic importance ensures consistent demand and high market value.